What happened with TECH today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Bio-Techne makes proteins, antibodies and other reagents that university laboratories, pharmaceutical companies and biotechnology companies buy to study biology and develop drugs and diagnostic tests. Its Protein Sciences business provides most of its sales and also sells instruments and assays for measuring proteins, including tools used in drug-production quality control. Consumables that customers use up in research and testing generate most of the company’s revenue; instruments and services contribute less.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Thermo Fisher Scientific competes with Bio-Techne for academic and biopharmaceutical laboratories’ spending on reagents and analytical tools, but also distributes Bio-Techne products. Watch its sales to those laboratories for a read on demand from Bio-Techne’s customers.
Bio-Rad Laboratories competes with Bio-Techne to sell protein-analysis instruments, assays and reagents to research laboratories and biopharmaceutical quality-control teams. Its Life Science business is the part to watch for demand from these shared customers.
Revvity competes with Bio-Techne for laboratory purchases of reagents and analytical tools for protein and cell research, drug discovery and molecular diagnostics. Watch its Life Sciences sales to pharmaceutical, biotechnology and contract research organizations rather than treating all its diagnostic sales as a Bio-Techne signal.
Danaher’s life-science businesses compete with Bio-Techne for researchers’ and biopharmaceutical developers’ purchases of protein-analysis and tissue-imaging tools.
Quanterix Corporation competes with Bio-Techne to sell research laboratories and biopharmaceutical companies protein-biomarker tests and spatial-biology instruments and consumables. Watch its Simoa platform’s sensitivity and instrument and consumable costs: these are competitive factors in measuring proteins in blood and other fluids.
Bruker competes with Bio-Techne for research and biopharmaceutical laboratories’ spending on tools that measure biological samples and reveal their spatial structure. Its biological-analysis and spatial-biology product launches are worth watching for competing capabilities and cost-effectiveness.
10x Genomics, Inc. competes directly with Bio-Techne for researchers’ tissue-analysis purchases: its Visium and Xenium platforms are alternatives to RNAscope assays and COMET instruments for studying where biological signals occur in tissue. Watch Visium and Xenium instrument and consumable sales, rather than its single-cell portfolio, for this rivalry.
Agilent Technologies competes with Bio-Techne to supply life-science researchers and diagnostic laboratories with biomolecular-analysis and tissue-diagnostic tools. Its biomolecular-analysis, pathology and companion-diagnostic offerings are the relevant products to watch.
Alamar Biosciences, Inc. competes with Bio-Techne’s tests that measure several proteins at once by selling NULISA assays and ARGO instruments to research laboratories, biopharmaceutical companies and contract research organizations. Watch its assay menu and ARGO installations for the reach of this protein-biomarker competitor.
Standard BioTools Inc.’s retained mass-cytometry instruments and reagents compete with Bio-Techne’s spatial-biology tools for research customers studying many tissue and biomarker features at once. Watch its continuing mass-cytometry business, including CyTOF, rather than the sold SomaScan business.
QIAGEN competes with Bio-Techne for research and diagnostic customers’ purchases of molecular tests, consumables and instruments that analyze biological samples. Its consumables and related revenue is the main line to watch for demand in these workflows.
Repligen Corp and Bio-Techne both depend on biologics manufacturing activity and investment in cell and gene therapies: Repligen sells manufacturing systems, while Bio-Techne sells development reagents and tools used in production and quality control. Repligen’s filtration and process-analysis sales offer a view of manufacturing demand behind Bio-Techne’s biologics tools.
Avantor and Bio-Techne share exposure to laboratory consumables spending and biopharmaceutical production: Avantor supplies laboratory reagents and production materials, while Bio-Techne sells specialized proteins and therapeutic-development reagents to overlapping life-science customers. Watch Avantor’s Laboratory Solutions and Bioscience Production sales for these two sources of demand.
Thermo Fisher Scientific, Inc. earningsTMO
Thermo Fisher both sells to laboratories and distributes Bio-Techne products, so its sales to academic and biopharmaceutical labs offer a read on spending by customers the two companies share.
Look at Thermo Fisher’s sales to laboratory and biopharmaceutical customers. Resilient sales would suggest those customers are still buying, supporting demand for Bio-Techne’s offerings to similar buyers; weaker sales would point to tighter customer spending, but would not reveal Bio-Techne’s own orders or sales through its distributor.
Repligen Corp earningsRGEN
Repligen sells systems used in biologics manufacturing, while Bio-Techne supplies reagents and tools for related development and production work; Repligen’s filtration and process-analysis sales offer a read on activity in those workflows.
Watch Repligen’s filtration and process-analysis sales. Strength would point to greater demand or investment in biologics manufacturing workflows, which could support Bio-Techne products used in development, production and quality control; weakness would suggest softer activity in those workflows, not prove how Bio-Techne itself performed.
Fed Interest Rate Decision
The Fed’s rate decision signals the direction of borrowing costs; because Bio-Techne has $200 million of variable-rate debt priced from SOFR, higher rates can raise interest expense and reduce earnings.
Expected4.0%Last release4.0%
If it comes in above expectations
If the Fed sets rates higher than expected, Bio-Techne’s variable-rate debt can become more expensive to service, raising interest expense and weighing on earnings.
If it comes in below expectations
If the Fed sets rates lower than expected, Bio-Techne’s variable-rate debt can become cheaper to service, reducing interest expense and easing pressure on earnings.
Bio-Techne Corp. earningsThis company
Bio-Techne’s Protein Sciences business brings in most of its revenue, and this report will show whether demand for its reagents and analytical tools can translate into sales despite product-mix and pricing pressure.
Read organic sales growth in Protein Sciences, especially consumables, alongside adjusted gross margin, which excludes specified items. Steady sales with a steady margin would show that laboratory demand is still turning into revenue without further pressure on the economics of the sales mix; weaker sales and a falling margin would point to continued demand or product-mix and pricing pressure.
Bio-Rad Laboratories, Inc. earningsBIO
Bio-Rad’s Life Science business competes with Bio-Techne for research laboratories’ and biopharmaceutical quality-control teams’ spending on protein-analysis instruments, assays and reagents.
Watch sales in Bio-Rad’s Life Science business. Steady sales would show that shared customers are still buying protein-analysis tools and reagents, supporting the market Bio-Techne serves; a decline would point to weaker spending, but would not prove Bio-Techne lost orders or market share.
10x Genomics, Inc. earningsTXG
10x Genomics’ Visium and Xenium platforms compete with Bio-Techne’s RNAscope assays and COMET instruments for tissue-analysis purchases, and its report will show how much traction those alternatives have.
Read 10x Genomics’ Visium and Xenium instrument sales alongside consumables sales. Strength in both would show researchers are adopting these tissue-analysis alternatives, increasing competitive pressure on Bio-Techne’s spatial-biology tools; weakness would suggest less traction, not prove Bio-Techne won the customers.
